肠道微生态与肿瘤的诊断和治疗

doi:10.3760/cma.j.cn371439-20201019-00084

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (7): 436-440.doi: 10.3760/cma.j.cn371439-20201019-00084

肠道微生态与肿瘤的诊断和治疗

安江宏¹, 钱莘², 骆璞¹, 谭晓华¹()

¹深圳市第三人民医院南方科技大学第二附属医院肿瘤血液科 518000
²解放军总医院第一医学中心呼吸与重症监护科,北京 100853

收稿日期:2020-10-19 修回日期:2020-11-05 出版日期:2021-07-08 发布日期:2021-07-26
通讯作者: 谭晓华 E-mail:xiaohua_t@hotmail.com

Application of gut microbiome in the diagnosis and treatment of tumor

An Jianghong¹, Qian Shen², Luo Pu¹, Tan Xiaohua¹()

¹Department of Oncology and Hematology, Third People's Hospital of Shenzhen, Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen 518000, China
²Department of Respiratory and Critical Care Medicine, First Medical Center, PLA General Hospital, Beijing 100853, China

Received:2020-10-19 Revised:2020-11-05 Online:2021-07-08 Published:2021-07-26
Contact: Tan Xiaohua E-mail:xiaohua_t@hotmail.com

摘要/Abstract

摘要：

肠道微生态与人类健康密切相关。肠道微生物组成特征改变促进肿瘤发生发展。特定肠道微生物及其代谢产物调节宿主生理功能和肿瘤微环境,显著影响抗肿瘤治疗反应及其不良反应。靶向肠道微生态的策略在肿瘤诊治中显示出有希望的应用前景。

关键词: 肠道微生态, 肿瘤微环境, 免疫治疗

Abstract:

Gut microbiome is closely related to human health. Changes in intestinal microbial composition promote the development of tumors. Specific intestinal microorganisms and their metabolites regulate host physiological functions and tumor microenvironment, significantly affecting the anti-cancer treatment response and its adverse events. Strategies targeting gut microbiome have shown promising prospects in diagnosis and treatment of cancer.

Key words: Gut microbiome, Tumor microenvironment, Immunotherapy

安江宏, 钱莘, 骆璞, 谭晓华. 肠道微生态与肿瘤的诊断和治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 436-440.

An Jianghong, Qian Shen, Luo Pu, Tan Xiaohua. Application of gut microbiome in the diagnosis and treatment of tumor[J]. Journal of International Oncology, 2021, 48(7): 436-440.

参考文献 30

[1]	Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy[J]. Nat Rev Cancer, 2017, 17(5):271-285. DOI: 10.1038/nrc.2017.13. doi: 10.1038/nrc.2017.13
[2]	Makki K, Deehan EC, Walter J, et al. The impact of dietary fiber on gut microbiota in host health and disease[J]. Cell Host Microbe, 2018, 23(6):705-715. DOI: 10.1016/j.chom.2018.05.012. doi: 10.1016/j.chom.2018.05.012
[3]	Huybrechts I, Zouiouich S, Loobuyck A, et al. The human micro-biome in relation to cancer risk: a systematic review of epidemiologic studies[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(10):1856-1868. DOI: 10.1158/1055-9965.epi-20-0288. doi: 10.1158/1055-9965.EPI-20-0288
[4]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494):973-980. DOI: 10.1126/science.aay9189. doi: 10.1126/science.aay9189
[5]	Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks⁺ E. coli[J]. Nature, 2020, 580(7802):269-273. DOI: 10.1038/s41586-020-2080-8. doi: 10.1038/s41586-020-2080-8
[6]	Dejea CM, Fathi P, Craig JM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria[J]. Science, 2018, 359(6375):592-597. DOI: 10.1126/science.aah3648. doi: 10.1126/science.aah3648
[7]	Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J]. Nat Commun, 2020, 11(1):2168. DOI: 10.1038/s41467-020-16079-x. doi: 10.1038/s41467-020-16079-x pmid: 32358520
[8]	Yu AI, Zhao L, Eaton KA, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis[J]. Cell Rep, 2020, 31(1):107471. DOI: 10.1016/j.celrep.2020.03.035. doi: 10.1016/j.celrep.2020.03.035
[9]	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103. DOI: 10.1126/science.aan4236. doi: 10.1126/science.aan4236 pmid: 29097493
[10]	肖俊娟, 毕振旺, 李岩. 肠道微生态与肿瘤免疫调节的相关研究[J]. 国际肿瘤学杂志, 2017, 44(1):34-37. DOI: 10.3760/cma.j.issn.1673-422x.2017.01.009.
[11]	Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes[J]. Cell, 2019, 178(4):795-806, e12. DOI: 10.1016/j.cell.2019.07.008. doi: S0092-8674(19)30773-1 pmid: 31398337
[12]	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018, 8(4):403-416. DOI: 10.1158/2159-8290.cd-17-1134. doi: 10.1158/2159-8290.CD-17-1134 pmid: 29567829
[13]	Ferrie S, Webster A, Wu B, et al. Gastrointestinal surgery and the gut microbiome: a systematic literature review[J]. Eur J Clin Nutr, 2020, In press. DOI: 10.1038/s41430-020-0681-9.
[14]	van Praagh JB, de Goffau MC, Bakker IS, et al. Mucus microbiome of anastomotic tissue during surgery has predictive value for colorectal anastomotic leakage[J]. Ann Surg, 2019, 269(5):911-916. DOI: 10.1097/sla.0000000000002651. doi: 10.1097/SLA.0000000000002651
[15]	Gaines S, van Praagh JB, Williamson AJ, et al. Western diet promotes intestinal colonization by collagenolytic microbes and promotes tumor formation after colorectal surgery[J]. Gastroenterology, 2020, 158(4):958-970, e2. DOI: 10.1053/j.gastro.2019.10.020. doi: S0016-5085(19)41471-6 pmid: 31655031
[16]	Darbandi A, Mirshekar M, Shariati A, et al. The effects of probio-tics on reducing the colorectal cancer surgery complications: a perio-dic review during 2007—2017[J]. Clin Nutr, 2020, 39(8):2358-2367. DOI: 10.1016/j.clnu.2019.11.008. doi: S0261-5614(19)33135-8 pmid: 31831184
[17]	Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies[J]. Microbiome, 2018, 6(1):92. DOI: 10.1186/s40168-018-0483-7. doi: 10.1186/s40168-018-0483-7 pmid: 29789015
[18]	Loman BR, Jordan KR, Haynes B, et al. Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice[J]. Sci Rep, 2019, 9(1):16490. DOI: 10.1038/s41598-019-52893-0. doi: 10.1038/s41598-019-52893-0 pmid: 31712703
[19]	Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563, e16. DOI: 10.1016/j.cell.2017.07.008. doi: 10.1016/j.cell.2017.07.008
[20]	Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction[J]. Gut, 2018, 67(1):97-107. DOI: 10.1136/gutjnl-2017-313789. doi: 10.1136/gutjnl-2017-313789 pmid: 28438965
[21]	Cui M, Xiao H, Li Y, et al. Faecal microbiota transplantation protects against radiation-induced toxicity[J]. EMBO Mol Med, 2017, 9(4):448-461. DOI: 10.15252/emmm.201606932. doi: 10.15252/emmm.201606932
[22]	Guo H, Chou WC, Lai Y, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites[J]. Science, 2020, 370(6516):eaay9097. DOI: 10.1126/science.aay9097. doi: 10.1126/science.aay9097
[23]	Liu MM, Li ST, Shu Y, et al. Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials[J]. PLoS One, 2017, 12(6):e0178870. DOI: 10.1371/journal.pone.0178870. doi: 10.1371/journal.pone.0178870
[24]	Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials[J]. Ann Oncol, 2020, 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. doi: S0923-7534(20)35927-5 pmid: 32115349
[25]	Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018, 24(12):1804-1808. DOI: 10.1038/s41591-018-0238-9. doi: 10.1038/s41591-018-0238-9
[26]	Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]. Ann Oncol, 2017, 28(6):1368-1379. DOI: 10.1093/annonc/mdx108. doi: 10.1093/annonc/mdx108 pmid: 28368458
[27]	Zheng DW, Chen Y, Li ZH, et al. Optically-controlled bacterial metabolite for cancer therapy[J]. Nat Commun, 2018, 9(1):1680. DOI: 10.1038/s41467-018-03233-9. doi: 10.1038/s41467-018-03233-9
[28]	Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510):1481-1489. DOI: 10.1126/science.abc3421. doi: 10.1126/science.abc3421
[29]	Gregory AC, Zablocki O, Zayed AA, et al. The Gut Virome Database reveals age-dependent patterns of virome diversity in the human gut[J]. Cell Host Microbe, 2020, 28(5):724-740, e8. DOI: 10.1016/j.chom.2020.08.003. doi: 10.1016/j.chom.2020.08.003
[30]	Lim B, Zimmermann M, Barry NA, et al. Engineered regulatory systems modulate gene expression of human commensals in the gut[J]. Cell, 2017, 169(3):547-558, e15. DOI: 10.1016/j.cell.2017.03.045. doi: 10.1016/j.cell.2017.03.045

肠道微生态与肿瘤的诊断和治疗

Application of gut microbiome in the diagnosis and treatment of tumor

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	傅旖, 马辰莺, 张露, 周菊英. 生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	刘筱迪, 苏剑飞, 张静娴, 卫雪芹, 贾英杰. 髓源性抑制细胞在肿瘤血管生成中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 50-54.
[6]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[7]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[8]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[9]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[10]	曹梦清, 徐志勇, 施毓婷, 王凯. 三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173.
[11]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[12]	黄华玉, 龚虹云, 宋启斌. 胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106.
[13]	张雨潇, 张连生, 李莉娟. 新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125.
[14]	张碧霞, 丁江华. EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[15]	朱易, 陈健. 硫化氢在肿瘤发生发展中的作用机制及其供体抗肿瘤作用[J]. 国际肿瘤学杂志, 2023, 50(12): 729-733.